Last reviewed · How we verify

Proteus Pyelonephritis — Treatment Landscape & Competitive Intelligence

Proteus Pyelonephritis (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Proteus Pyelonephritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Maxipime CEFEPIME Baxter Cephalosporin Antibacterial 1996-01-01
Maxipime Cefepime Hydrochloride Baxter Cephalosporin Bacterial cell wall peptidoglycan 1996-01-01
Cefepim Cefepim University Hospital Tuebingen Bacterial penicillin-binding protein

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Baxter · 2 drugs in Proteus Pyelonephritis
  2. University Hospital Tuebingen · 1 drug in Proteus Pyelonephritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Proteus Pyelonephritis:

Cite this brief

Drug Landscape (2026). Proteus Pyelonephritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/proteus-pyelonephritis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing